Abstract
The expression of retinoid acid receptors alpha (RARalpha) and beta (RARbeta) and estrogen receptor alpha (ERalpha) was assessed by immunohistochemistry and Western blotting in normal ovaries, serous cystadenoma (n = 20), serous borderline (n = 14), and serous ovarian cancer (n = 47) and was correlated in cancer cases with stage, grade, progress-free survival (PFS), and survival. RARalpha was increasingly expressed in benign cystadenomas, borderline, and low-stage and advanced-stage neoplasms (p < 0.001). In stage III, G3 serous carcinoma, increased RARalpha expression was an independent prognostic factor associated with lower chemoresponse to first-line chemotherapy (taxol and carboplatin) and shorter PFS (p < 0.002).RARbeta and ERalpha expression did not correlate with RARalpha tumor characteristics or PFS and survival.
(c) 2008 S. Karger AG, Basel
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Biomarkers, Tumor / analysis*
-
Blotting, Western
-
CA-125 Antigen / blood
-
Cystadenocarcinoma, Serous / chemistry*
-
Cystadenocarcinoma, Serous / drug therapy
-
Cystadenocarcinoma, Serous / pathology
-
Cystadenoma, Serous / chemistry*
-
Cystadenoma, Serous / drug therapy
-
Cystadenoma, Serous / pathology
-
Disease-Free Survival
-
Estrogen Receptor alpha / analysis*
-
Female
-
Gene Expression Regulation, Neoplastic
-
Humans
-
Immunohistochemistry
-
Middle Aged
-
Neoplasm Staging
-
Ovarian Neoplasms / chemistry*
-
Ovarian Neoplasms / drug therapy
-
Ovarian Neoplasms / pathology
-
Predictive Value of Tests
-
Prognosis
-
Radiography, Abdominal
-
Receptors, Retinoic Acid / analysis*
-
Retinoic Acid Receptor alpha
-
Tomography, X-Ray Computed
-
Treatment Outcome
Substances
-
Biomarkers, Tumor
-
CA-125 Antigen
-
Estrogen Receptor alpha
-
RARA protein, human
-
Receptors, Retinoic Acid
-
Retinoic Acid Receptor alpha
-
retinoic acid receptor beta